News & Events
-
August 29, 2023
Externally-Led Patient Focused Drug Development
C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) and the PKD Foundation will be hosting an Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for Autosomal Recessive Polycystic Kidney Disease (ARPKD) on Tuesday, August 29th. EL-PFDD meetings bring together patients and care partners, US Food and Drug Administration (FDA) representatives, pharmaceutical companies, physicians, and researchers who are... -
July 21, 2023 - July 23, 2023
8th International RASopathies Symposium: Expanding Research and Care Practice through Global Collaboration and Advocacy
Members of the CDRC team will be attending the upcoming event: Expanding Research and Care Practice through Global Collaboration and Advocacy on July 21-23. Dysregulation of cellular RAS-RAF-MEK-ERK signaling is not only responsible for a third of all human cancers; it underlies a large group of human genetic syndromes collectively termed RASopathies. RASopathies include neurofibromatosis... -
June 25, 2023 - June 29, 2023
DIA 2023 Global Annual Meeting | ILLUMINATE
The DIA 2023 Global Annual Meeting invites industry, regulatory government, academics, and patients to network, problem-solve, and discuss global and local challenges facing the life sciences community. Hosted in Boston, key C-Path personnel will be on-hand to discuss and view the many different perspectives offered at this event, while highlights expertise across the globe to... -
June 14, 2023 - June 15, 2023
CeBil Symposium
The CeBil symposium marks the conclusion of the Novo Nordisk Foundation’s Collaborative Research Program in Biomedical Innovation Law (the CeBIL-program), which has been running since 2018. Leading international experts will discuss the ethical, legal, and social, and policy implications (ELSPI) of selected challenges and opportunities in the health and life sciences. This event has two... -
June 7, 2023
Newcastle University’s John Walton Muscular Dystrophy Research Centre Contributes Data to C-Path’s RDCA-DAP
C-Path announced today that Newcastle University UK’s John Walton Muscular Dystrophy Research Centre will contribute data to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) managed by C-Path. These data come from the Myotubular (MTM) and Centronuclear Myopathy (CNM) Patient Registry and the Global Registry for COL6-related dystrophies.